M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes.
Masahiro Takada,Masakazu Toi +1 more
TL;DR: Cryoablation for primary tumor may enhance the treatment effect of immune checkpoint inhibitors in patients with breast cancer and induces an immunomodulatory effect, which is an interesting topic of research in the era of immune checkpoints inhibitors.
Journal ArticleDOI
BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).
Sara A. Hurvitz,Fabrice Andre,Howard A. Burris,Masakazu Toi,Marc Buyse,Tarek Sahmoud,Pabak Mukhopadhyay,Cristian Massacesi,Tanya Taran,Jennifer Ko,Matthieu Rupin +10 more
TL;DR: Everolimus, an orally bioavailable inhibitor of mammalian target of rapamycin (mTOR), a protein kinase central to multiple protein synthesis pathways and implicated in trastuzumab resistance, and everolimus-containing regimens have shown promising results in patients with ER+, HER2– advanced BC in phase II/III trials.
Journal ArticleDOI
Trastuzumab: updates and future issues
TL;DR: A more precise understanding of the mechanisms of therapeutic response is needed so that trastuzumab-based therapies can be optimized more individually and the interaction between the Her-axis and the hormone-axis is investigated.
Journal ArticleDOI
Clinical Significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant.
Sara M. Tolaney,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Eva-Maria Grischke,Antonio Llombart-Cussac,Hatem Soliman,Hong Wang,Sameera R. Wijayawardana,Valerie M. Jansen,Lacey M. Litchfield,George W. Sledge +11 more
TL;DR: Abemaciclib plus fulvestrant was effective regardless of PIK3CA or ESR1 mutation status, with benefit in both PFS and OS, with a numerically greater improvement in median PFS relative to placebo plus ful vestrant for PIK1-mutant tumors compared to the respective wild-type subgroups.
Journal ArticleDOI
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
Masakazu Toi,Tadashi Ikeda,Futoshi Akiyama,Masafumi Kurosumi,Hitoshi Tsuda,Goi Sakamoto,Osahiko Abe +6 more
TL;DR: TS, but not TP or DPD, may be a useful predictor of response to UFT therapy, suggesting that 2 years of treatment with oral fluorouracil derivatives may be inadequate.